BTK Inhibitors in CLL: Key Clinical Updates From ASCO & EHA 2025

Decera Clinical Education Oncology Podcast · Jul 23, 2025 · 21m

In this episode, James Davis, PharmD, BCOP and Victoria Nachar, PharmD, BCOP summarize the latest key clinical updates on BTK inhibitors in CLL based on data recently presented at the annual ASCO and EHA meetings, including:

The randomized phase III FLAIR trial

The randomized phase III SEQUOIA trial

The randomized phase III BRUIN CLL-321 trial

Presenters:

James Davis, PharmD, BCOP

Clinical Pharmacy Specialist, Malignant Hematology

MUSC Hollings Cancer Center

Assistant Professor

MUSC College of Pharmacy

Charleston, South Carolina

Victoria Nachar, PharmD, BCOP

Clinical Pharmacist Specialist…